Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Jiangsu Hengrui Medicine Co., Ltd.
  6. Summary
    600276   CNE0000014W7

JIANGSU HENGRUI MEDICINE CO., LTD.

(600276)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
01/17/2022 01/18/2022 01/19/2022 01/20/2022 01/21/2022 Date
46.41 46.21 45.73 45.69 44.94 Last
39411430 35422090 41324750 35022530 44690110 Volume
-0.51% -0.43% -1.04% -0.09% -1.64% Change
Estimated financial data (e)
Sales 2021 29 321 M 4 626 M 4 626 M
Net income 2021 6 646 M 1 049 M 1 049 M
Net cash position 2021 18 323 M 2 891 M 2 891 M
P/E ratio 2021 40,8x
Yield 2021 0,43%
Sales 2022 32 485 M 5 125 M 5 125 M
Net income 2022 7 553 M 1 192 M 1 192 M
Net cash position 2022 22 439 M 3 540 M 3 540 M
P/E ratio 2022 36,5x
Yield 2022 0,46%
Capitalization 286 B 45 167 M 45 171 M
EV / Sales 2021 9,14x
EV / Sales 2022 8,12x
Nbr of Employees 28 903
Free-Float 46,5%
More Financials
Company
Jiangsu Hengrui Pharmaceuticals Co Ltd is a China-based company principally engaged in the manufacture and distribution of pharmaceutical tablets, injections and raw materials. The Company's main products portfolio consists of antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents, antibiotics, specialty infusions and others. The Company distributes its products within domestic market and to... 
Sector
Pharmaceuticals
Calendar
04/19Earnings Release
More about the company
Ratings of Jiangsu Hengrui Medicine Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about JIANGSU HENGRUI MEDICINE CO., LTD.
2021CStone Pharma Grants Jiangsu Hengrui Rights to Investigational Cancer Drug in Greater C..
MT
2021Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended S..
CI
2021BeyondSpring Shares Up 17% After China Commercialization Deal
DJ
2021Dalian Wanchun Brin Pharmaceutical Co., Ltd. announced that it expects to receive CNY 1..
CI
2021Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the Half Year Ended Jun..
CI
2021MARKET CHATTER : China Adds New Drugs to Cover Under Health Insurance Program
MT
2021China stocks slip as healthcare firms retreat; Hong Kong up
RE
2021Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announces on Obtaining Notice of Approval of ..
CI
2021Shanghai Fosun Pharmaceutical's H-Shares Surge to All-Time High
DJ
2021Jiangsu Hengrui Medicine Co., Ltd. Reports Earnings Results for the First Quarter Ended..
CI
2021EXCLUSIVE : China's JD.com in talks to buy stake worth $1.5 billion in brokerage - sources
RE
2021Jiangsu Hengrui Medicine Co., Ltd. Announces Approval of Conducting Clinical Trial in U..
CI
2021MARKET CHATTER : Jiangsu Hengrui Medicine to Invest $20 Million in Drug Research Company U..
MT
2021Yingli Pharma and Hengrui Medicine Reach a Strategic Agreement to Jointly Explore the O..
CI
2020Drugmakers agree to halve prices to get on China state insurance list
RE
More news
News in other languages on JIANGSU HENGRUI MEDICINE CO., LTD.
2021CStone Pharma accorde à Jiangsu Hengrui les droits sur un médicament expérimental contr..
2021DISCUSSIONS SUR LE MARCHÉ : La Chine ajoute de nouveaux médicaments à la liste des médicam..
2021EXCLUSIF : La société chinoise JD.com est en pourparlers pour acheter une participation d'..
2021SINOLINK SECURITIES : JD.com négocie son entrée au capital du courtier Sinolink
2021DISCUSSIONS SUR LE MARCHÉ : Jiangsu Hengrui Medicine va investir 20 millions de dollars da..
More news
Chart JIANGSU HENGRUI MEDICINE CO., LTD.
Duration : Period :
Jiangsu Hengrui Medicine Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JIANGSU HENGRUI MEDICINE CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 44,94 CNY
Average target price 69,56 CNY
Spread / Average Target 54,8%
EPS Revisions
Managers and Directors
Wei Dong Chairman-Supervisory Board
Piao Yang Sun Chairman
Shuang Xue Independent Director
Qian Wang Independent Director
Jia Hong Dong Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JIANGSU HENGRUI MEDICINE CO., LTD.-11.38%45 167
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356